3D digital scanning shortens denture-fitting time from days to minutes

"The process of fitting dentures hasn't significantly changed in the last 100 years," said Dr. Anat Sharon, Director of the Maxillofacial Prosthetics Clinic at Hadassah Medical Center. "It is such a long process that most dental clinics simply refuse to carry out the procedure."

The BioDesign: Medical Innovation program, a joint effort of the Hebrew University of Jerusalem and the Hadassah Medical Center, allowed Sharon to recruit top engineering and business students to help her develop an alternative technology.

"HoloDent is the first holography scanning device for intraoral 3D modeling, reducing the time it takes to get dentures from 30 days to 30 minutes, while making the treatment far more comfortable and precise for all patients," said Amit Zilberstein, a BioDesign fellow and CEO of the HoloDent company. The group won a recent award at the Startup Open Israel competition and participated at the MassChallenge acceleration program in Boston, Massachusetts earlier this year.

"HoloDent is a testament to the immense creativity and drive of our students," said Prof. Yaakov Nahmias, director of Israel's BioDesign program. "The experience and maturity of our fellows are predicates to successful spin-offs such as HoloDent."

The technology addresses a market of $500 million in the United States alone. HoloDent also aims to improve the accessibility of accurate denture fitting for aging populations in developing countries, eliminating the need for a dentist in those areas by providing access to a cost-effective digital solution.

BioDesign is a multi-disciplinary, team-based approach to medical innovation, created by the Hebrew University of Jerusalem and the Hadassah Medical Center. The program, sponsored by Boston Scientific and the Terumo Medical Corporation, takes outstanding medical fellows, bioengineering and business graduate students, and tutors them in the science and practice of bringing a medical innovation to the market. The innovations produced by the Biodesign program are commercialized by Yissum, the technology transfer company of the Hebrew University of Jerusalem, and Hadasit, the technology transfer company of the Hadassah Medical Center.

The BioDesign program is directed by Prof. Yaakov Nahmias, director of the Alexander Grass Center for Bioengineering at the Hebrew University of Jerusalem, and Prof. Chaim Lotan, director of the Heart Institute at Hadassah Medical Center. For more information, visit http://cbsh.cs.huji.ac.il/.